Sign in
Taking peoplePhase 1/2

Testing NN2802 in healthy people and adults with chronic spontaneous urticaria

Tests NN2802 in healthy adults and adults with chronic spontaneous urticaria despite antihistamines.

Key facts

Who runs it
Novelty Nobility, Inc.
Where
China1 site in 1 countryChoose a country to see its sites
Trial code
Registry title
A Study of NN2802, an Anti-c-Kit Antibody, in Healthy Participants and in Adults With Chronic Spontaneous Urticaria (CSU)
Status
Recruiting
Phase
Phase 1/2
People taking part
46 people, planned
Started
15 Oct 2026
Expected to end
31 Mar 2028
Type of study
Interventional, 6 groups
Treatments tested
  • NN2802
Record updated
12 November 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for healthy adults (Part A) and adults with chronic spontaneous urticaria (CSU, long-lasting hives without a known cause) who still have symptoms despite antihistamines (Part B).

Age
Part A: 18 to 65 years. Part B: 18 to 75 years.
Sex
Men and women can join.
Disease stage
Part B: CSU diagnosed at least 6 months ago, with itch and hives for at least 6 weeks in a row. Symptoms not controlled by H1-antihistamines, alone or with a leukotriene receptor antagonist, for at least 2 weeks in a row. UAS7 of 16 or more and ISS7 of 8 or more in the 7 days before treatment. In-clinic UAS of 4 or more on one screening day. Part A: healthy, BMI between 18.0 and 26.0 kg/m2. Part B: weight 40 kg (88 lb) or more.
Earlier treatment
Part B: earlier anti-IgE therapy (such as omalizumab) is allowed if the last dose was at least 5 half-lives before randomization. People who have had NN2802 before cannot join. Part B: no immunosuppressive drugs within 60 days before dosing.
Biomarker or test result
Part A: liver tests and creatinine at or below the upper limit of normal, and a negative tuberculosis test at screening.

Main reasons for not taking part

  • Pregnancy or breastfeeding
  • Hives with a clear cause, or other diseases causing hives or swelling, such as mastocytosis or hereditary angioedema
  • Cancer within the past 5 years, with some skin and in situ cancers excepted
  • Positive test for HIV, hepatitis B or hepatitis C, or recent serious infection
  • History of anaphylaxis or significant allergies

The registry criteria, word for word

Show all 61 criteriaShow less

Who can take part

  • Participants must sign an IRB/IEC approved informed consent form before any study specific procedures are performed
  • Healthy adult male and female participants between 18 and 65 years of age, inclusive, at the time of screening
  • Participants must have suitable veins for cannulation or repeated venipuncture
  • If female, meets one the of following criteria:; Is of childbearing potential and agrees to use a highly effective contraceptive method from at least 28 days prior to the Screening visit through to at least 105 days after study drug administration; OR; Is of non-childbearing potential, defined as surgically sterile, or is in a postmenopausal state
  • If male, meets one the following criteria:; Abstinence from penile vaginal intercourse as their usual and preferred lifestyle; Unable to procreate, defined by surgically sterile; Agrees to use male condom when having sexual intercourse with a woman of childbearing potential
  • Body mass index (BMI) between 18.0 and 26.0 kg/m2, inclusive
  • Normal or clinically acceptable physical examination, clinical laboratory test values, ECG, and vital signs, as determined by the Investigator
  • Total bilirubin, ALT, AST and creatinine ≤ upper limit of normal (ULN)
  • No known history of active tuberculosis
  • Participant has a negative tuberculosis test at screening
  • Participants must sign an IRB/IEC approved ICF before any study-specific procedures are performed
  • Adult male and female participants between 18 and 75 years of age, inclusive, at the time of screening
  • Weight ≥40 kg
  • Diagnosis of CSU refractory to H1-antihistamines used alone or in combination with a leukotriene receptor antagonist, at the time of randomization, as defined by all the following:; CSU diagnosis ≥ 6 months, with supporting documentation; Presence of itch and hives for ≥ 6 consecutive weeks at any time prior to enrollment, including inadequate disease control despite treatment with H1-antihistamines, either alone or in combination with leukotriene receptor antagonists, for at least 2 consecutive weeks during this period; UAS7 (range 0-42) of ≥16 and ISS7 (range 0-21) of ≥8 during the 7 days before treatment; In-clinic UAS ≥4 on one of the screening visit days, despite use of H1 antihistamines alone or in combination with H2-antihistamines and or leukotriene receptor antagonist) for CSU
  • Prior anti-immunoglobulin E (IgE) therapy is allowed (e.g., omalizumab), with the last dose administered at least 5 half-lives of the respective drug prior to randomization
  • If female, meets one the of following criteria:; Is of childbearing potential and agrees to use a highly effective contraceptive method. OR; Is of non-childbearing potential, defined as surgically sterile, or is in a postmenopausal state
  • If male, meets one the following criteria:; Abstinence from penile vaginal intercourse as their usual and preferred lifestyle; Unable to procreate, defined by surgically sterile; Agrees to use male condom when having sexual intercourse with a woman of childbearing potential

Who cannot take part

  • Female who is pregnant according to the pregnancy test at screening or prior to study drug administration or plans to become pregnant during the study or within 105 days following study drug dosing
  • Consume more than 14 units of alcohol per week (if male) or consume more than 11 units of alcohol per week (if female), or history of alcohol or drug/chemical abuse within 12 months prior to study drug dosing, as determined by the Investigator
  • Positive drugs of abuse (including marijuana) or alcohol screen test
  • Participants who have used the following within 7 days of dosing, unless in the opinion of the Investigator the medication will not interfere with the study procedures or compromise safety:; any non-prescribed (i.e., over-the-counter) systemic or topical medication; any herbal remedy, vitamin, or mineral supplement
  • Received any medications, including St. John's Wort, known to chronically alter drug absorption or elimination processes, within 30 days prior to dosing, unless in the opinion of the Investigator the medication will not interfere with the study procedures or compromise safety
  • Is currently participating in another clinical study or has received an investigational medicinal product (IMP) within the following time period prior to dosing: 30 days, 5 half-lives, or twice the duration of the biological effect of the IMP (whichever is longer)
  • Participants who have previously received NN2802
  • History or evidence of any bacterial, viral, parasitic, or system fungal infections within 30 days prior to dosing. Exception: a simple, short duration common cold resolved more than 14 days prior to dosing
  • Recent infection (within 3 months prior to dosing) requiring inpatient hospitalization or IV antibiotics
  • Clinically significant illness, medical/surgical procedure, or trauma within 4 weeks prior to dosing, as determined by the Investigator
  • Received or scheduled to receive a live vaccination within 3 months prior to dosing and until 3 months following study drug dosing
  • Previously enrolled in or withdrawn from this study
  • Females who are lactating, or who are pregnant according to the pregnancy test at screening or prior to study drug administration, or plan to become pregnant during the study
  • Participants who have received:; immunosuppressive drugs (e.g., cyclosporine, tacrolimus) within 60 days prior to dosing; COVID-19 vaccination within 30 days prior to dosing; Standard vaccinations within 14 days prior to dosing or other live or live attenuated vaccine 3 months prior to dosing; Previous use of IgE therapy (e.g., Omalizumab) within 5 half-lives of the respective anti-IgE therapy prior to dosing
  • Is currently participating in another clinical study or has received an investigational medicinal product (IMP) within the following time period prior to dosing: 30 days, five half-lives, or twice the duration of the biological effect of the IMP (whichever is longer)
  • Participants who have previously received NN2802 or any other c-kit targeting agent within the following time period prior to dosing: 30 days, five half-lives, or twice the duration of the biological effect of the IMP (whichever is longer)
  • Active infection or history of infection as follows:; Any active infection for which oral anti-infectives (antibiotics, antivirals, antifungals) were used ≤ 14 days prior to first dose of study drug); A serious infection requiring hospitalization or IV anti-infectives (antibiotics, antivirals, antifungals) ≤ 30 days prior to first dose of study drug; Recurrent or chronic infections or other active infections that in the opinion of the investigator might cause this study to be detrimental to the participant
  • Clinically significant illness, medical/surgical procedure, or trauma within 4 weeks prior to dosing, as determined by the Investigator
  • Received or scheduled to receive a live vaccination within 3 months prior to dosing and until 3 months following study drug dosing
  • Previously enrolled in or withdrawn from this study
  • Active substance abuse (drug or alcohol) within 24 weeks prior to first dose of study drug, as determined by the investigator
  • History of anaphylaxis, clinically significant drug allergies or allergic conditions (excluding non-active seasonal allergies), as determined by the Investigator
  • History of malignancy within 5 years prior to dosing, except treated and considered cured cutaneous squamous or basal cell carcinoma, in situ cervical cancer, or in situ breast ductal carcinoma
  • History or evidence of any clinically significant disorder (including psychiatric), condition, or disease that, in the opinion of the Investigator, may pose a risk to participant safety or interfere with the study evaluation, procedures, or completion
  • Infectious Disease Risk; Participants will be excluded if any of the following apply at screening:; Positive test for HIV (Human immunodeficiency virus) antibodies; Positive or indeterminate HBsAg, or positive IgM HBcAb, or positive Total HBcAb and positive HBV DNA, or positive HCV Ab and positive HCV RNA
  • Clearly defined cause for chronic urticaria, including any of the following:; Symptomatic solar-, cholinergic-, heat-, cold-, aquagenic- or contact induced urticaria, artificial urticaria, symptomatic urticaria or vibratory angioedema; Diseases with symptoms of urticaria and/or angioedema, such as: urticarial vasculitis, urticaria pigmentosa, erythema multiforme, mastocytosis, hereditary or acquired angioedema, hematological or any other malignancies
  • History or evidence of any clinically significant disorder (including psychiatric), condition, or disease other than CSU, that, in the opinion of the investigator, may pose a risk to participant safety or interfere with the study evaluation, procedures, or completion
  • Uncontrolled, clinically significant system disease such as diabetes mellitus, cardiovascular disease including moderate-to-severe heart failure (New York Heart Association class III/IV), moderate-to-severe liver disease, or hypertension, as determined by the Investigator
  • History of anaphylaxis, clinically significant drug or food allergies or any other clinically significant allergic conditions (e.g., excluding mild seasonal allergies), as determined by the Investigator
  • History of hypersensitivity or allergy to NN2802 or its excipients
  • History of malignancy within 5 years prior to dosing, except treated and considered cured cutaneous squamous or basal cell carcinoma, in situ cervical cancer, or in situ breast ductal carcinoma
  • Known or clinically suspected active helminthic parasitic infection, as determined by the Investigator based on medical history and clinical presentation
  • Infectious Disease Risk; Participants will be excluded if any of the following apply at screening:; Positive test for HIV (Human immunodeficiency virus) antibodies; Positive or indeterminate HBsAg, or positive IgM HBcAb, or positive Total HBcAb and positive HBV DNA, or positive HCV Ab and positive HCV RNA; Tuberculosis (TB) risk
  • Donated blood in the 3 months prior to screening, plasma in the 7 days prior to screening, or platelets in the 6 weeks prior to screening
  • Participants who have received:; any prescribed systemic or topical medication within 14 days or 5 half-lives (whichever is longer) prior to dosing, unless in the opinion of the Investigator the medication will not interfere with the study procedures or compromise safety; any antihistamines within 5 half-lives prior to dosing; immunosuppressive drugs within 60 days prior to dosing; COVID-19 vaccination within 30 days prior to dosing; standard vaccinations within 14 days prior to dosing or other live or live-attenuated vaccine 3 months prior to dosing; slow-release medicinal formulations considered to still be active within 14 days or 5 half-lives (whichever is longer) prior to dosing, unless in the opinion of the Investigator the medication will not interfere with the study procedures or compromise safety; for male participants, medications that are known to affect sperm count or motility within 30 days prior to dosing
  • Laboratory abnormalities at screening:
  • Female who is lactating
  • Participants who smoke more than 9 cigarettes, or equivalent in tobacco per day, or inability to abide by the smoking policy of the clinical research unit
  • Inability or unwillingness to reside at the clinical research unit during the confinement period, or inability to be available for follow-up visits or protocol required procedures
  • Participants who, in the opinion of the Investigator, should not participate in this study
  • Anticipated requirement for the use of any leukotriene receptor antagonist (Montelukast, Zafirlukast) use between Day 1 and EOS (inclusive)
  • Clinically significant electrocardiogram (ECG) findings unless approved by Cardiologist or Study Medical Monitor
  • Inability or unwillingness to be available for follow-up visits or protocol required procedures
  • Participants who, in the Investigator's opinion, should not participate in this study

The main criteria, as questions

These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Are you between 18 and 75 years old?

This trial is currently available in China.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

NN2802 is a new product that is being developed for treating participants with CSU who remain symptomatic despite treatment with antihistamines. NN2802 is not yet an approved product and it can only be used in an experimental study like this one.

Read full original descriptionShow less

The purpose of this study is to learn more about a new experimental drug called NN2802. NN2802 is an investigational fully human monoclonal antibody that inhibits c-Kit. c-Kit is involved in the survival, development, and activity of mast cells, which are important cells involved in allergic and inflammatory reactions. By inhibiting c-Kit, NN2802 may reduce mast cell numbers and activity and may help improve symptoms of CSU, such as hives, itching, and angioedema.

The study will assess the safety, tolerability, pharmacokinetics (PK, amount of drug in your blood), pharmacodynamics (PD, how the drug affects your body), immunogenicity (whether your body develops antibodies against the study drug), and preliminary efficacy (whether the drug may improve CSU symptoms) of NN2802. It also aims to identify suitable doses and dosing schedules of NN2802 for use in future clinical trials.

This study will be conducted at multiple study sites, involving around 44 to 46 participants in total, including healthy participants and participants with CSU who remain symptomatic despite treatment with antihistamines. The number of participants depends on how well the study participants tolerate the treatment and the number of dose groups studied.

The 6 groups in the trial

  • Part A-1Treatment being tested

    NN2802 Dose 1 or placebo administered intravenously once

    Treatment: NN2802

  • Part A-2Treatment being tested

    NN2802 Dose 2 or placebo administered intravenously once

    Treatment: NN2802

  • Part B-1Treatment being tested

    NN2802 Dose 1 administered intravenously Q8W

    Treatment: NN2802

  • Part B-2 HighTreatment being tested

    NN2802 Dose administered intravenously Q8W or Q4W

    Treatment: NN2802

  • Part B-2 MidTreatment being tested

    NN2802 Dose administered intravenously Q8W or Q4W

    Treatment: NN2802

  • Part B-2 LowTreatment being tested

    NN2802 Dose administered intravenously Q8W or Q4W

    Treatment: NN2802

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Phase 1/2a, Randomized, Double-Blind, Placebo-Controlled (With an Open-Label Part B-1 Cohort), Single Dose and Multiple Dose Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of NN2802, in Healthy Participants and in Participants With Chronic Spontaneous Urticaria (CSU) Who Remain Symptomatic Despite Treatment With Antihistamines
Plain-language title
Testing NN2802 in healthy people and adults with chronic spontaneous urticariaGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 15 November 2026.
Criteria questions
Built from NCT07930572, who can take part
Record updated
12 November 2026